Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  West Pharmaceutical Services Inc.    WST

WEST PHARMACEUTICAL SERVICES INC. (WST)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Sales1 4001 5091 5991 7251 8612 047
EBITDA280315337382434510
Operating profit (EBIT)190224240278322393
Pre-Tax Profit (EBT)------
Net income95,6144151216249312
P/E ratio46,344,449,630,126,021,1
EPS ( $ )1,301,911,992,913,364,14
Dividend per Share ( $ )0,460,50-0,560,600,67
Yield0,76%0,59%-0,64%0,69%0,76%
Reference price ( $ )60.2284.8398.6787.4587.4587.45
Announcement Date02/18/2016
12:00pm
02/16/2017
12:17pm
02/15/2018
06:52pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201520162017201820192020
Debt-25,6----
Finance--38,9166287415
Operating income (EBITDA)280315337382434510
Leverage
(Debt/EBITDA)
-0,08x----
Capital Expenditure132170131161157155
Book Value Per Share (BVPS)14,2 $15,3 $-19,6 $22,8 $26,7 $
Cash Flow per Share2,88 $2,93 $-4,25 $4,84 $5,79 $
Announcement Date02/18/2016
12:00pm
02/16/2017
12:17pm
02/15/2018
06:52pm
---
Balance Sheet Analysis
Assessed data source :
© 2018 Thomson Reuters
Financial Ratios

Size 2018e 2019e
Capitalization 6 493 M$ -
Entreprise Value (EV) 6 328 M$ 6 206 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 30,1x 26,0x
Capitalization / Revenue 3,76x 3,49x
EV / Revenue 3,67x 3,33x
EV / EBITDA 16,5x 14,3x
Yield (DPS / Price) 0,64% 0,69%
Price to book (Price / BVPS) 4,47x 3,84x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 16,1% 17,3%
operating Leverage (Delta EBIT / Delta Sales) 2,00x 2,00x
Net Margin (Net Profit / Revenue) 12,5% 13,4%
ROA (Net Profit / Asset) 10,5% 11,4%
ROE (Net Profit / Equities) 15,0% 15,5%
Rate of Dividend 19,1% 17,8%
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   9,33% 8,45%
Cash Flow / Sales 18,3% 19,3%
Capital Intensity (Assets / Sales) 1,19x 1,17x
Financial Leverage (Net Debt / EBITDA) -0,43x -0,66x
EPS & Dividend